Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Thermo Fisher Scientific Inc. is a leading provider of scientific instruments, reagents, and consumables, primarily serving the healthcare and life sciences sectors. The company benefits from a diversified portfolio, including its strong presence in biopharma services and diagnostics, which positions it well against competitors in a growing market.
Thermo Fisher generates revenue through the sale of scientific instruments, reagents, and consumables, leveraging its strong brand reputation and extensive distribution network. The company enjoys pricing power due to its innovative product offerings and established customer relationships, particularly in the biopharma sector.
Demand for COVID-19 testing and related products
Growth in biopharma R&D spending
New product launches in analytical instruments
Acquisitions that enhance product offerings or market share
Regulatory changes affecting the healthcare industry
Technological disruption from new entrants in diagnostics
Intensifying competition from other life sciences companies
Potential for pricing pressure in commoditized product segments
Moderate debt levels could constrain financial flexibility in downturns
Pension obligations may pose long-term financial risks
moderate - The company's performance is linked to healthcare spending and R&D investment, which can be cyclical but generally remains resilient during economic downturns.
Thermo Fisher's financing costs could be impacted by rising interest rates, which may affect capital expenditures and acquisition strategies, though the company's strong cash flow mitigates this risk.
minimal - The company has a manageable debt-to-equity ratio of 0.81, indicating low reliance on external financing.
growth - The company is positioned for continued growth in the healthcare sector, particularly in diagnostics and biopharma.
moderate - Historical volatility is relatively low, reflecting stable demand for its products.
